MESO action tonight, page-542

what if I told you that Mesoblast was able to demonstrate a similar success rate in another trial.. using the exact same stem cells.

The same cells were used in an extensive compassionate use program for aGVHD sufferers (approx. 240), and 55 in a phase 3 trial, where MSB's cells were able to stop the cytokine storm in aGVHD sufferers where the host's immune system will reject the transplanted bone marrow... that would result in a 10-30% survival rate for aGVHD sufferers based on historical data.

The phase 3 trial demonstrated a 69% survival rate for aGVHD sufferers, which was similar to the compassionate use program. This is now in the process of being approved by the FDA in the US, with an outcome due in the second half of 2020. BLA submission already in... just a waiting game.

Now if this 300 patient COVID19 ARDS trial demonstrates a 69% survival rate vs a 12% survival rate ... the compassionate use program has shown that we have a good chance that the cells are working similarly to shut down the cytokine storm causing the the immune system to overreact and flood the lungs.